The DOI matches its Crossref record; the references it cites are not checked yet.
Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort
Open accessAbstract
Background and Objectives Recent advances in blood-based biomarkers offer the potential to revolutionize the diagnosis and management of Alzheimer disease (AD), but additional research in diverse populations is critical. We assessed the profiles of blood-based AD biomarkers and their relationships to cognition and common medical comorbidities in a biracial cohort. Methods Participants were evaluated through the Mayo Clinic Jacksonville Alzheimer Disease Research Center and matched on age, sex, and cognitive status. Plasma AD biomarkers (β-amyloid peptide 1–42 [Aβ42/40], plasma tau phosphorylated at position 181 [p-tau181], glial fibrillary acidic protein [GFAP], and neurofilament light) were measured using the Quanterix SiMoA HD-X analyzer. Cognition was assessed with the Mini-Mental State Examination. Wilcoxon rank sum tests were used to assess for differences in plasma biomarker levels by sex. Linear models tested for associations of self-reported race, chronic kidney disease (CKD), and vascular risk factors with plasma AD biomarker levels. Additional models assessed for interactions between race and plasma biomarkers in predicting cognition. Results The sample comprised African American (AA; N = 267) and non-Hispanic White (NHW; N = 268) participants, including 69% female participants and age range 43–100 (median 80.2) years. Education was higher in NHW participants (median 16 vs 12 years, p < 0.001) while APOE ε4 positivity was higher in AA participants (43% vs 34%; p = 0.04). We observed no differences in plasma AD biomarker levels between AA and NHW participants. These results were unchanged after stratifying by cognitive status (unimpaired vs impaired). Although the p-tau181-cognition association seemed stronger in NHW participants while the Aβ42/40-cognition association seemed stronger in AA participants, these findings did not survive after excluding individuals with CKD. Female participants displayed higher GFAP (177.5 pg/mL vs 157.73 pg/mL; p = 0.002) and lower p-tau181 (2.62 pg/mL vs 3.28 pg/mL; p = 0.001) levels than male participants. Diabetes was inversely associated with GFAP levels (β = −0.01; p < 0.001). Discussion In a biracial community-based sample of adults, we observed that sex differences, CKD, and vascular risk factors, but not self-reported race, contributed to variation in plasma AD biomarkers. Although some prior studies have reported primary effects of race/ethnicity, our results reinforce the need to account for broad-based medical and social determinants of health (including sex, systemic comorbidities, and other factors) in effectively and equitably deploying plasma AD biomarkers in the general population.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, a recent study of a biracial, community-based sample of adults found no independent association of plasma AD biomarkers based on selfreported race, with age, sex, chronic kidney disease and vascular risk factors contributing to observed variation. (459)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [459]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 39 · Cited by 89
Research works printed but not linked: 2
- Centers for Disease Control and Prevention. National Diabetes Statistics Report website [online]. Accessed January 25, 2023. cdc.gov/diabetes/data/statistics-report/index.html.
- Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System website [online]. Accessed January 25, 2023. nccd.cdc.gov/ckd/default.aspx.
Metadata
- Authors
- Ramanan, V. K., Graff-Radford, J., Syrjanen, J., Shir, D., Algeciras-Schimnich, A., Lucas, J., Martens, Y. A., Carrasquillo, M. M., Day, G. S., Ertekin-Taner, N., Lachner, C., Willis, F. B., Knopman, D. S., Jack, C. R., Petersen, R. C., Vemuri, P., Graff-Radford, N., & Mielke, M. M.
- Affiliations
- Mayo Clinic (US)
- From the Department of Neurology (V.K.R., J.G.-R., D.S., D.S.K., R.C.P.), Department of Quantitative Health Sciences (J.S., R.C.P.), and Department of Laboratory Medicine and Pathology (A.A.-S.), Mayo Clinic, Rochester, MN; Department of Psychiatry and Psychology (J.L., C.L.), Department of Neuroscience (Y.A.M., M.M.C., G.S.D., N.E.-T.), Department of Neurology (N.E.-T., C.L., N.G.-R.), and Department of Family Medicine (F.B.W.), Mayo Clinic, Jacksonville, FL; Department of Radiology (C.R.J., P.V.),...
- ORCID
- Venue
- Neurology
- Published
- 2023-10-03
- Volume
- 101
- Issue
- 14
- Pages
- e1402-e1411
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC10573134
- OpenAlex
- W4385803548
- Cited by
- 89
- References
- 39
- Citations by year
- 2026: 20 · 2025: 39 · 2024: 28 · 2023: 2
- FWCI
- 18.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- Mayo Clinic (U01 AG046139, RR018898, P30 AG062677, P50 AG016574, U01 AG006786, R01AG034676)
- Eli Lilly and Company
- Biogen
- University of Southern California
- Florida Department of Health
- Mayo Foundation for Medical Education and Research (AG034676, AG016574, R01-AG034676)
- Horizon Pharmaceuticals
- GHR Foundation (R01 AG034676)
- University of Oxford
- Eisai
- Siemens Healthineers
- National Institutes of Health (AG016574, AG046139, AG062677, AG011378)
- Genentech
- National Institute on Aging (R01AG034676, RF1AG051504, U01AG057195, RF1AG077386, U01AG006786, RF1AG069052, K23AG064029, U01AG046139, R01AG061796, U19AG032438, R33AG058738, R01AG041851, R37AG011378, R01AG056366, P30AG062677, U19AG074879, P50AG016574)
- National Institute of Neurological Disorders and Stroke (R01NS097495)
- National Center for Research Resources (C06RR018898)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, plasma biomarkers, blood-based biomarkers, phosphorylated tau 181, glial fibrillary acidic protein, neurofilament light chain, cognition, chronic kidney disease, vascular risk factors, diabetes mellitus, sex differences, racial differences, African Americans, non-Hispanic whites, APOE ε4
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Female, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort. https://app.cochat.ai/papers/10.1212/wnl.0000000000207675
- The paper
- Ramanan, V. K., Graff-Radford, J., Syrjanen, J., Shir, D., Algeciras-Schimnich, A., Lucas, J., Martens, Y. A., Carrasquillo, M. M., Day, G. S., Ertekin-Taner, N., Lachner, C., Willis, F. B., Knopman, D. S., Jack, C. R., Petersen, R. C., Vemuri, P., Graff-Radford, N., & Mielke, M. M. (2023). Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort. Neurology. https://doi.org/10.1212/wnl.0000000000207675
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.